Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement Of Results In Connection With The Tender Offer Made By Glenmark Pharmaceuticals Limited (The 'Company') To The Holders Of Its Outstanding U.S.$200,000,000 2.00 Per Cent. Resettable Onward Starting Equity-Linked Securities Due 2022

 Announcement of results in connection with the tender offer made by Glenmark Pharmaceuticals Limited (the 'Company') to the holders of its outstanding U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022
27-03-2021
Bigul

Glenmark gets USFDA nod for generic antipsychotic drug

 Company granted competitive generic therapy (CGT) designation for these tablets, making it eligible for 180 days of CGT exclusivity upon commercial marketing
24-03-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity
24-03-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity
23-03-2021

Glenmark joins hands with Bausch to commercialise nasal spray in Canada

 The company's subsidiary, Glenmark Specialty SA in Switzerland and an affiliate of Bausch Health Companies Inc have entered into an exclusive licensing agreement for the commercialisation of Glenmark''s innovative nasal spray Ryaltris under review by Health Canada, the Mumbai-based firm said in a regulatory filing.
22-03-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark and Bausch Health join together to commercialize RYALTRIS (tm) nasal spray in Canada
22-03-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Invitation By Glenmark Pharmaceuticals Limited (The 'Company') To The Holders Of Its Outstanding U.S.$200,000,000 2.00 Per Cent. Resettable Onward Starting Equity-Linked Securities Due 2022 ('Bonds') To Tender Such Bonds For Purchase By The Company For Cash And To Approve The Amendment To The Optional Put Notice Period Of The Bonds.

 With respect to the above subject, we have made an announcement in the Singapore Exchange Securities Trading Limited dated March 19, 2021. Please find enclosed herewith a copy of the same as Annexure A. You are requested to take the same on record.
19-03-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Invitation By Glenmark Pharmaceuticals Limited (The 'Company') To The Holders Of Its Outstanding U.S.$200,000,000 2.00 Per Cent. Resettable Onward Starting Equity-Linked Securities Due 2022 ('Bonds') To Tender Such Bonds For Purchase By The Company For Cash And To Approve The Amendment To The Optional Put Notice Period Of The Bonds.

 The Company had issued the Bonds in 2016 which are currently listed on the Singapore Exchange Securities Trading Limited. Pursuant to our intimation letters dated 9 February 2021 and 12 February 2021, and the powers delegated to the Operations Committee by the Board of Directors of the Company, the Operations Committee in their meeting held today, approved inter alia (i) the launch of an invitation by the Company to the holders of its outstanding Bonds to tender such Bonds for purchase by the Company for cash and to approve the amendment to the optional put notice period of the Bonds as detailed in and in accordance with the terms and conditions of the Tender Offer and Solicitation Memorandum dated March 19, 2021 (the 'TOSM'), the material terms of which are summarized in Annexure A; and (ii) the appointment of the Hongkong and Shanghai Banking Corporation Limited as dealer manager for this purpose.
19-03-2021
Bigul

Glenmark Pharma signs Rohit Sharma as brand ambassador for Candid Powder

 Drug major Glenmark Pharma on Friday said it has signed cricketer Rohit Sharma as brand ambassador for its product Candid Powder.
05-03-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder
05-03-2021
Next Page
Close

Let's Open Free Demat Account